pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Ophthalmology · news · pharmadog
← back to Ophthalmology
News · Ophthalmology
406
stories
27d
Health insurance premiums jump 9%, and more Americans don’t have access to coverage
stat
27d
Roivant's TYK2/JAK inhibitor reduces need for steroids in inflammatory eye disease
biospace
28d
ESMO 2026: Merck’s Kelun-partnered ADC hits the ‘Goldilocks zone,’ VP says
biospace
28d
STAT+: Another diabetes association leader is out while review continues
stat
28d
Roivant, continuing ascent, claims another victory for rare disease drug
biopharma dive
28d
Alcon and OpenAI make acquisitions; Tezspire's latest Phase 3 win
endpoints
28d
STAT+: GSK picks up hep B drug approval
stat
28d
STAT+: Pharmalittle: We’re reading about Mark Cuban eyeing rare disease drugs, a ketamine gold rush, and more
stat
28d
STAT+: Roivant says closely watched immune drug succeeded in new eye disease
stat
28d
Nigeria identifies travel-related Ebola case
stat
28d
STAT+: A German biotech has big ambitions in cancer. Now it needs to get a medicine approved
stat
28d
STAT+: Mark Cuban wants to crack open the market for rare disease treatments
stat
29d
Exclusive: Astellas partners with Boston ‘miniproteins’ startup
endpoints
29d
Gilead’s ‘highly competitive’ mid-stage ulcerative colitis data ‘validate’ I&I push
biospace
29d
Opinion: Resident physicians may lose some of their most important work hour protections
stat
Oct 20, 26
FDA, MHRA officials eye streamlined frameworks for regulating genAI
raps
Oct 19, 26
EyePoint will halve workforce, end pivotal wet AMD trials early following second fail
biospace
Oct 19, 26
As AbbVie’s Crohn’s combo beats Skyrizi in mid-stage test, analysts laud autoimmune vision
biospace
Oct 19, 26
EyePoint's Phase 3 failure; Lilly's China drug delivery deal
endpoints
Oct 19, 26
Investment firm TCGX picks migraine biotech TriGemX to take public via SPAC
fiercebiotech
Oct 19, 26
Roche returns to China’s ADC powerhouse Hansoh for $15B biobucks pact
fiercebiotech
Oct 19, 26
Merck/Moderna, Summit/Akeso and ADCs to headline ESMO 2026
biospace
Oct 16, 26
Iambic CEO on taking an AI drug company public
biopharma dive
Oct 16, 26
STAT+: Pharmalittle: We’re reading about an HHS peptide push, Trump’s pharma stock holdings, and more
stat
Oct 16, 26
City’s IPO soars to $200M, with proceeds supporting thromboembolic disease pipeline
biospace
Oct 16, 26
OrbiMed raises two new life sciences funds worth $3B with one aiming for Asia
biospace
Oct 16, 26
Next-gen RNAi drugmaker City prices $200M IPO
biopharma dive
Oct 15, 26
Chutes & Ladders—Bausch + Lomb's returning CEO Saunders exits again
fiercebiotech
Oct 15, 26
Vanda freezes Novartis-originated social anxiety program after late-stage disappointment
biospace
Oct 15, 26
AstraZeneca inks $1.5B insitro deal for AI-enabled target discovery of liver, heart disease drugs
fiercebiotech
← prev
page 4 of 14
next →